SEBI fines CDSL for cyber lapses; L&T secures mega orders
Indian equities face mixed signals as a SEBI penalty highlights depository cyber risks while L&T and Grasim signal strong domestic industrial demand.
India's market regulator has fined Central Depository Services (CDSL) Rs 1 crore for cybersecurity and operational failures that enabled a malware attack in November 2022. The Securities and Exchange Board of India (SEBI) determined the depository failed to properly secure critical infrastructure despite stricter regulatory requirements.
The penalty underscores growing regulatory scrutiny over digital infrastructure at India's financial market utilities. For investors, the fine serves as a reminder of the operational risks inherent in depository businesses, which act as the backbone of the country's equity clearing and settlement system. Any prolonged disruption to these systems would have immediate systemic implications for market functioning.
On the industrial front, Larsen & Toubro (L&T) said its Metals & Minerals division has won multiple mega orders from domestic public and private mining companies. The contracts are for engineering, procurement and construction (EPC) solutions across the metals value chain.
These wins reinforce L&T's dominant position in India's EPC sector and point to sustained capital deployment within the domestic mining industry. For the conglomerate's order book, the influx of mega projects provides strong revenue visibility for coming quarters. It also indicates that private and state-run miners are moving forward with expansion plans despite global commodity price volatility.
Separately, Grasim Industries has deployed nearly Rs 74,000 crore in capital expenditure across its businesses over the past five years. Chairman Kumar Mangalam Birla framed the outlay as a proxy for the group's confidence in long-term demand and India's broader economic trajectory.
Such sustained heavy investment signals that major Indian industrial houses continue to bet aggressively on domestic capacity expansion. It suggests corporate leadership anticipates enduring structural demand rather than a short-term cyclical uptick. Investors often view this kind of multi-year capital deployment as a reliable indicator of a company's internal growth forecasts.
In the pharmaceutical sector, Emcure Pharmaceuticals announced its co-marketed semaglutide brand, Poviztra, is now available for fatty liver treatment. Semaglutide has generated massive global demand for diabetes and weight loss, and expanding its indications allows Emcure to capture more value from the existing drug partnership. The expansion of the drug's approved use cases broadens Emcure's addressable market in the lucrative metabolic disease space.
